These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

915 related articles for article (PubMed ID: 29892070)

  • 1. An inhibitor of oxidative phosphorylation exploits cancer vulnerability.
    Molina JR; Sun Y; Protopopova M; Gera S; Bandi M; Bristow C; McAfoos T; Morlacchi P; Ackroyd J; Agip AA; Al-Atrash G; Asara J; Bardenhagen J; Carrillo CC; Carroll C; Chang E; Ciurea S; Cross JB; Czako B; Deem A; Daver N; de Groot JF; Dong JW; Feng N; Gao G; Gay J; Do MG; Greer J; Giuliani V; Han J; Han L; Henry VK; Hirst J; Huang S; Jiang Y; Kang Z; Khor T; Konoplev S; Lin YH; Liu G; Lodi A; Lofton T; Ma H; Mahendra M; Matre P; Mullinax R; Peoples M; Petrocchi A; Rodriguez-Canale J; Serreli R; Shi T; Smith M; Tabe Y; Theroff J; Tiziani S; Xu Q; Zhang Q; Muller F; DePinho RA; Toniatti C; Draetta GF; Heffernan TP; Konopleva M; Jones P; Di Francesco ME; Marszalek JR
    Nat Med; 2018 Jul; 24(7):1036-1046. PubMed ID: 29892070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OXPHOS-targeting drugs in oncology: new perspectives.
    Kalyanaraman B; Cheng G; Hardy M; You M
    Expert Opin Ther Targets; 2023; 27(10):939-952. PubMed ID: 37736880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.
    Yap TA; Daver N; Mahendra M; Zhang J; Kamiya-Matsuoka C; Meric-Bernstam F; Kantarjian HM; Ravandi F; Collins ME; Francesco MED; Dumbrava EE; Fu S; Gao S; Gay JP; Gera S; Han J; Hong DS; Jabbour EJ; Ju Z; Karp DD; Lodi A; Molina JR; Baran N; Naing A; Ohanian M; Pant S; Pemmaraju N; Bose P; Piha-Paul SA; Rodon J; Salguero C; Sasaki K; Singh AK; Subbiah V; Tsimberidou AM; Xu QA; Yilmaz M; Zhang Q; Li Y; Bristow CA; Bhattacharjee MB; Tiziani S; Heffernan TP; Vellano CP; Jones P; Heijnen CJ; Kavelaars A; Marszalek JR; Konopleva M
    Nat Med; 2023 Jan; 29(1):115-126. PubMed ID: 36658425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.
    Farge T; Saland E; de Toni F; Aroua N; Hosseini M; Perry R; Bosc C; Sugita M; Stuani L; Fraisse M; Scotland S; Larrue C; Boutzen H; Féliu V; Nicolau-Travers ML; Cassant-Sourdy S; Broin N; David M; Serhan N; Sarry A; Tavitian S; Kaoma T; Vallar L; Iacovoni J; Linares LK; Montersino C; Castellano R; Griessinger E; Collette Y; Duchamp O; Barreira Y; Hirsch P; Palama T; Gales L; Delhommeau F; Garmy-Susini BH; Portais JC; Vergez F; Selak M; Danet-Desnoyers G; Carroll M; Récher C; Sarry JE
    Cancer Discov; 2017 Jul; 7(7):716-735. PubMed ID: 28416471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation.
    Liu F; Kalpage HA; Wang D; Edwards H; Hüttemann M; Ma J; Su Y; Carter J; Li X; Polin L; Kushner J; Dzinic SH; White K; Wang G; Taub JW; Ge Y
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [
    Gammon ST; Pisaneschi F; Bandi ML; Smith MG; Sun Y; Rao Y; Muller F; Wong F; De Groot J; Ackroyd J; Mawlawi O; Davies MA; Gopal YNV; Di Francesco ME; Marszalek JR; Dewhirst M; Piwnica-Worms D
    Cells; 2019 Nov; 8(12):. PubMed ID: 31766580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myeloid leukemia sensitivity to metabolic inhibitors: glycolysis showed to be a better therapeutic target.
    Lapa B; Gonçalves AC; Jorge J; Alves R; Pires AS; Abrantes AM; Coucelo M; Abrunhosa A; Botelho MF; Nascimento-Costa JM; Sarmento-Ribeiro AB
    Med Oncol; 2020 Jul; 37(8):72. PubMed ID: 32725458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
    Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
    J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer.
    Curry JM; Tuluc M; Whitaker-Menezes D; Ames JA; Anantharaman A; Butera A; Leiby B; Cognetti DM; Sotgia F; Lisanti MP; Martinez-Outschoorn UE
    Cell Cycle; 2013 May; 12(9):1371-84. PubMed ID: 23574725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting mitochondrial RNA polymerase in acute myeloid leukemia.
    Bralha FN; Liyanage SU; Hurren R; Wang X; Son MH; Fung TA; Chingcuanco FB; Tung AY; Andreazza AC; Psarianos P; Schimmer AD; Salmena L; Laposa RR
    Oncotarget; 2015 Nov; 6(35):37216-28. PubMed ID: 26484416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue.
    Whitaker-Menezes D; Martinez-Outschoorn UE; Flomenberg N; Birbe RC; Witkiewicz AK; Howell A; Pavlides S; Tsirigos A; Ertel A; Pestell RG; Broda P; Minetti C; Lisanti MP; Sotgia F
    Cell Cycle; 2011 Dec; 10(23):4047-64. PubMed ID: 22134189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
    Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
    Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of mitochondrial oxidative phosphorylation by chidamide eradicates leukemic cells in AML.
    Wang JD; Xu JQ; Long ZJ; Weng JY
    Clin Transl Oncol; 2023 Jun; 25(6):1805-1820. PubMed ID: 36899123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting neddylation modification alters mitochondrial morphology and reprograms energy metabolism in cancer cells.
    Zhou Q; Li H; Li Y; Tan M; Fan S; Cao C; Meng F; Zhu L; Zhao L; Guan MX; Jin H; Sun Y
    JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30668548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic Enzyme DLST Promotes Tumor Aggression and Reveals a Vulnerability to OXPHOS Inhibition in High-Risk Neuroblastoma.
    Anderson NM; Qin X; Finan JM; Lam A; Athoe J; Missiaen R; Skuli N; Kennedy A; Saini AS; Tao T; Zhu S; Nissim I; Look AT; Qing G; Simon MC; Feng H
    Cancer Res; 2021 Sep; 81(17):4417-4430. PubMed ID: 34233924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer.
    Evans KW; Yuca E; Scott SS; Zhao M; Paez Arango N; Cruz Pico CX; Saridogan T; Shariati M; Class CA; Bristow CA; Vellano CP; Zheng X; Gonzalez-Angulo AM; Su X; Tapia C; Chen K; Akcakanat A; Lim B; Tripathy D; Yap TA; Francesco MED; Draetta GF; Jones P; Heffernan TP; Marszalek JR; Meric-Bernstam F
    Cancer Res; 2021 Nov; 81(21):5572-5581. PubMed ID: 34518211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition.
    Saito K; Zhang Q; Yang H; Yamatani K; Ai T; Ruvolo V; Baran N; Cai T; Ma H; Jacamo R; Kuruvilla V; Imoto J; Kinjo S; Ikeo K; Moriya K; Suzuki K; Miida T; Kim YM; Vellano CP; Andreeff M; Marszalek JR; Tabe Y; Konopleva M
    Blood Adv; 2021 Oct; 5(20):4233-4255. PubMed ID: 34507353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759.
    Pujalte-Martin M; Belaïd A; Bost S; Kahi M; Peraldi P; Rouleau M; Mazure NM; Bost F
    Mol Oncol; 2024 Jul; 18(7):1719-1738. PubMed ID: 38214418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells.
    Vangapandu HV; Alston B; Morse J; Ayres ML; Wierda WG; Keating MJ; Marszalek JR; Gandhi V
    Oncotarget; 2018 May; 9(38):24980-24991. PubMed ID: 29861847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia.
    Yehudai D; Liyanage SU; Hurren R; Rizoska B; Albertella M; Gronda M; Jeyaraju DV; Wang X; Barghout SH; MacLean N; Siriwardena TP; Jitkova Y; Targett-Adams P; Schimmer AD
    Haematologica; 2019 May; 104(5):963-972. PubMed ID: 30573504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.